摘要
目的探讨金乌骨通胶囊联合骨肽片治疗颈椎骨质增生的临床疗效。方法选取2019年5月—2020年5月在中国平煤神马医疗集团总医院进行治疗的226例颈椎骨质增生患者为研究对象,根据就诊顺序分为对照组(113例)和治疗组(113例)。对照组口服骨肽片,0.6 g/次,3次/d;治疗组在对照组基础上口服金乌骨通胶囊,1.5 g/次,3次/d。两组均经15 d治疗。比较两组的临床疗效,观察两组治疗前后中医症候积分、相关评分和椎动脉血流速度参数的变化情况。结果治疗后,治疗组总有效率是97.35%显著高于对照组的82.30%(P<0.05)。治疗后,两组颈项酸痛积分、肩背酸痛积分、活动受限积分、肢体麻木积分、头晕目眩积分等中医症候积分均较治疗前显著降低(P<0.05);治疗后,治疗组这些中医症候积分显著低于对照组(P<0.05)。治疗后,两组CASCS评分、ESCV评分、QLQC30评分均显著升高,但NDI评分显著降低(P<0.05);治疗后,治疗组CASCS评分、ESCV评分、QLQC30评分显著高于对照组,而NDI评分显著低于对照组(P<0.05)。经治疗,两组平均血流速度(VM)、舒张末期血流速度(VD)、收缩期血流速度(VP)均较治疗前显著升高(P<0.05);治疗后治疗组这些椎动脉血流速度参数显著高于对照组(P<0.05)。结论金乌骨通胶囊联合骨肽片治疗颈椎骨质具有较好的临床疗效,可有效改善患者临床症状,提高颈部活动能力,改善眩晕程度及椎动脉血流速度,有利于提高患者生活质量,具有一定的临床推广应用价值。
Objective To investigate the clinical effect of Jinwu Gutong Capsules mbined with Ossotide Tablets in treatment of cervical hyperosteogeny.Methods 226 Patients with cervical hyperosteogeny admitted to China Pingmei Shenma Medical Group General Hospital from May 2019 to May 2020 were divided into control group(113 cases)and treatment group(113 cases)according to the order of treatment.The control group was po administered with Ossotide Tablets,0.6 g/time,three times dialy.The treatment group was po administered with Jinwu Gutong Capsules on the basis of the control group,1.5 g/time,three times dialy.All patients were treated for 15 days.The clinical efficacy of the two groups was compared,and the changes of TCM syndrome scores,correlation scores and vertebral artery blood flow velocity parameters in two groups before and after treatment were observed.Results After treatment,the total effective rate in the treatment group was 97.35%,significantly higher than that in the control group(82.30%,P<0.05).After treatment,the scores of traditional Chinese medicine symptoms such as neck pain,shoulder and back pain,limited activity,numbness and dizziness in both groups were significantly lower than before treatment(P<0.05).After treatment,the scores of TCM syndromes in the treatment group were significantly lower than those in the control group(P<0.05).After treatment,CASCS score,ESCV score and QLQC30 score in both groups were significantly increased,but NDI score was significantly decreased(P<0.05).After treatment,CASCS score,ESCV score and QLQC30 score in the treatment group were significantly higher than those in the control group,while NDI score was significantly lower than that in the control group(P<0.05).After treatment,average blood flow velocity(VM),end-diastolic blood flow velocity(VD)and systolic blood flow velocity(VP)in both groups were significantly increased compared with that before treatment(P<0.05).After treatment,the flow velocity parameters of these vertebral arteries in the treatment group were significa
作者
潘登
杨红杰
高纯志
郭阿雷
虞鑫
郝申申
李杰一
PAN Deng;YANG Hong-jie;GAO Chun-zhi;GUO A-le;YU Xin;HAO Shen-shen;LI Jie-yi(Department of Spine Surgery,China Pingmei Shenma Medical Group General Hospital,Pingdingshan 467000,China;Department of Nephrorheumatology,Kaifeng People's Hospital,Kaifeng 475002,China)
出处
《现代药物与临床》
CAS
2020年第8期1613-1616,共4页
Drugs & Clinic
基金
开封市科技发展计划项目(1903069)。
